Abstract:Abstract Abstract 4023 Naturally occurring regulatory T cells (nTregs) may prevent graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) activity. However, clinical application of nTregs has been severely hampered by their scarce availability and non-selective suppression. To overcome these limitations, we took the alternative approach to induce antigen-specific Tregs (iTregs) and tested their efficacy and selectivity in the prevention of GVHD in a pre-clinical model of bone marrow transplantation (BMT). We selected HY as target antigen, because it is a naturally processed and ubiquitously expressed minor histocompatibility antigen (miHAg) with a proven role in GVHD and GVL effect. To generate HY-specific iTregs, naïve CD4+CD25− cells were isolated from MHC II-restricted, HY-specific transgenic and Foxp3/GFP knock-in mice, and were stimulated with HY peptide and APC, in the presence of TGFb and retinoic acid. Marrow plus polyclonal CD4 T effector cells (Teffs) from B6 donor splenocytes induced GVHD when transplanted into lethally irradiated (B6 x bm12)F1 recipients, and adoptive transfer of HY-specific iTregs (CD4+CD25+GFP+) significantly decreased GVHD mortality in male (HY+) but not female (HY−) recipients. On a per cell basis, HY-specific iTregs were significantly more potent than polyclonal Tregs in the prevention of GVHD. These data indicate that HY-specific iTregs were effective in controlling GVHD in an activation-dependent manner. Because polyclonal Teffs cells recognize bm12 alloantigen whereas iTregs recognize HY miHAg, these data suggest that Tregs may control GVHD through a linked-suppression on Teffs in vivo. Mechanistically, by measuring iTregs and Teffs in spleen and liver of the recipients, we found that HY-specific iTregs expanded extensively and significantly suppressed expansion and infiltration of Teffs in male but not female recipients. We finally generated alloreactive iTregs from polyclonal CD4 precursors, and found that these iTregs highly suppressed the Teffs alloresponse in vitro and in vivo. These results show that Ag-specific iTregs are promising cell therapy for effective GVHD prevention in human allogeneic hematopoietic cell transplantation. Disclosures: No relevant conflicts of interest to declare.

Regulatory T-Cell Therapy for Graft-versus-host Disease.

Regulatory T Cells in GVHD Therapy

Role of regulatory T lymphocytes in prevention and treatment of graft versus host disease

The impact of regulatory T cells on the graft-versus-leukemia effect

CD8+Tregs Promote GVHD Prevention and Overcome the Impaired GVL Effect Mediated by CD4+Tregs in Mice

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Engineered Regulatory T Cells Prevent Graft-Versus-host Disease While Sparing the Graft-Versus-leukemia Effect after Bone Marrow Transplantation.

Prevention Of Graft-Versus-Host Disease By Hy-Specific Induced Tregs Through Activation-Dependent Manner

Newly Found Peacekeeper: Potential of CD8+Tregs for Graft-Versus-Host Disease

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant

Efficient And Selective Prevention Of Graft-Versus-Host Disease By Ag-Specific Induced Regulatory T Cells In Mice

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells

Advances in the treatment of graft-versus-host disease with immunomodulatory cells

T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?

Efficient and Selective Prevention of GVHD by Antigen-Specific Induced Tregs Via Linked-Suppression in Mice.

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Graft-versus-Host Disease Modulation by Innate T Cells